Overwhelming Efficacy Demonstrated in Phase 3 HAELLO Study

Intellia Therapeutics (NTLA) announced that its in vivo gene editing therapy, lonvo-z (active ingredient: lonvoguran ziclumeran), has achieved positive results in the global Phase 3 HAELLO study, which evaluated the therapy in patients with Hereditary Angioedema (HAE). The study met both primary and key secondary endpoints. Compared to the placebo group, lonvo-z demonstrated a significant reduction in the mean monthly rate of angioedema attacks by 87% during the treatment period, clearly demonstrating its ability to control the disease. Notably, 62% of patients treated with lonvo-z achieved an attack-free status, meaning they experienced no angioedema attacks or required additional prophylactic treatment during the 6-month observation period, compared to 11% in the placebo group. This represents a significant improvement in treatment outcomes, potentially offering a single-dose treatment option for patients who previously required continuous chronic prophylactic therapy.

Addressing Safety Concerns and Initiating FDA Approval Process

One of the most encouraging findings from this trial is that lonvo-z demonstrated a favorable safety profile, with no serious adverse events related to off-target effects or liver toxicity, which have been historical challenges for gene editing therapies. The most commonly observed adverse events were infusion-related reactions, headache, and fatigue, which were mild to moderate in severity. There were no treatment-related permanent discontinuations, further supporting the favorable safety profile. Based on this robust data, Intellia has initiated a rolling submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). If the regulatory review process proceeds as planned, the company anticipates completing the commercial launch in the U.S. market in the first half of 2027.

Intensifying Competition in the Hereditary Angioedema Market

Lonvo-z targets the global HAE treatment market, which is currently estimated at approximately $3.1 billion and is expected to reach up to $6.5 billion, with projected growth to over $20 billion in the early 2030s. This represents a high-value rare disease area. However, competition is intensifying, with Takeda's monoclonal antibody therapy, Takhzyro, and BioCryst's oral therapy, Orladeyo, currently holding significant market share. Furthermore, in the second half of 2025, KalVista's on-demand acute attack therapy, Ekterly, and Ionis' prophylactic nucleic acid therapy, Dawnzera, and CSL Behring's FXIIa inhibitor antibody therapy, Andembry, are expected to receive FDA approval, further intensifying the competition.

Paradigm Shift as a 'One-Shot' Therapy and Overcoming Limitations

Lonvo-z utilizes an innovative mechanism that permanently inactivates the kallikrein B1 (KLKB1) gene in hepatocytes, thereby preventing the excessive production of bradykinin, which causes vasodilation. This represents a paradigm shift towards functional cure, offering a single-dose treatment option that addresses the underlying cause of the disease, unlike existing therapies that require lifelong periodic injections or oral medications. However, the industry recognizes that the high cost of gene therapies and potential delays in initial insurance coverage are key challenges that need to be addressed. Some experts also suggest that further validation of long-term safety data related to gene editing will be crucial for commercial success.